Chongqing Taiji Industry (Group) Co Ltd (Taiji Group, stock code: 600129) is a holding company of China National Pharmaceutical Group Co Ltd (Sinopharm) dedicated to inheriting and innovating traditional Chinese medicine (TCM) and developing modern medicine.

It operates 13 drug manufacturing factories, over 20 pharmaceutical companies, two research and development institutions and more than 3,000 chain pharmacies, most of which are located in Sichuan province and Chongqing municipality. With 14,000 staff in total, its business covers pharmaceutical R&D, industry and commerce.

Its main business is intelligent manufacturing of modern TCM, supplemented by the production of anesthetics and psychiatric drugs. It has a syrup production line with an annual capacity of 100 million bottles, an oral liquid production line with an annual capacity of 2 billion bottles, a pre-processing workshop and extraction and concentration workshop capable of handling 100,000 tons of herbal medicines annually.

It owns designated producers of anesthetics and psychiatric drugs in Southwest China and is equipped with advanced technologies, such as sustained- and controlled- release, instant release, dropping pills, and sustained-release dropping pills. It has Chinese time-honored brand Tongjunge and six national, provincial, municipal and district-level intangible cultural heritage items, including Tongjunge traditional pill-making techniques.

The company has obtained nearly 300 authorized patents, over 1,200 drug approvals, including nearly 700 TCM approvals and more than 500 chemical drug approvals, about 800 medical insurance varieties and 400 essential medicines. Among them, there are more than 10 varieties with annual sales exceeding 100 million yuan ($13.9 million) and nearly 100 varieties with annual sales exceeding 10 million yuan.

It has consecutively ranked as one of China’s Top 100 Pharmaceutical Companies by the Ministry of Industry and Information Technology (MIIT). It was awarded the title of national intellectual property demonstration enterprise in 2016. It ranked 13th in the Brand Finance Chinese Pharma 2021 and has received the integration of informatization and industrialization certificate from the MIIT.

The company’s TCM extraction center has passed the MIIT’s technical review of the pharmaceutical industry digitalization project. Its two chain pharmacy brands -- Tongjunge and Taiji -- have won such awards as Chinese Commercial Famous Brand and Top 100 Chinese Pharmaceutical Retail Enterprises.

It ranked sixth in the 2019-2020 China Pharmacy Value ranking and eighth in the Top 100 Comprehensive Strength ranking. It was rated second in the Comprehensive Statistical Ranking of China’s over the Counter Drug Manufacturers in 2021 and approved as the first national TCM service export base in Chongqing in March 2022.

In terms of scientific research, the company established a national-level postdoctoral workstation in 1998, and its technology center was recognized as a national enterprise technology center in 1999.

The company has successfully developed over 40 new drugs with more than 30 national certificates, and was awarded three China Patent Gold Awards. It has recently undertaken nearly 30 major special projects from the Ministry of Science and Technology, the National Development and Reform Commission and the MIIT, as well as over 50 provincial-level projects.

It has also undertaken five national-level projects for the cultivation and research of TCM materials and eight key provincial-level scientific and technological projects. It has been repeatedly rated as one of the key national leading enterprises in agricultural industrialization.

Taiji Group will strive tirelessly to become a world-class TCM enterprise to safeguard human health.